A new pyrroline compound selective for I1-imidazoline receptors improves metabolic syndrome in rats.

@article{Fellmann2013ANP,
  title={A new pyrroline compound selective for I1-imidazoline receptors improves metabolic syndrome in rats.},
  author={Lyne Fellmann and V{\'e}ronique R{\'e}gnault and Hugues Greney and Vincent Gasparik and Adeline Muscat and Jean-Pierre Max and Luc Gigou and Val{\'e}rie Or{\'e}a and G{\'e}rard Samuel Chetrite and Anne Pizard and Nathalie Niederhoffer and Claude Julien and Patrick Lacolley and Bruno F{\`e}ve and Pascal P Bousquet},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2013},
  volume={346 3},
  pages={370-80}
}
Symptoms of the metabolic syndrome (MetS), such as insulin resistance, obesity, and hypertension, have been associated with sympathetic hyperactivity. In addition, the adiponectin pathway has interesting therapeutic potentials in MetS. Our purpose was to investigate how targeting both the sympathetic nervous system and the adipose tissue (adiponectin secretion) with a drug selective for nonadrenergic I1-imidazoline receptors (I1Rs) may represent a new concept in MetS pharmacotherapy. LNP599 [3… CONTINUE READING